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Abstract
Background: The putative promoter of the holocarboxylase synthetase (HLCS) gene on chromosome 21 is hypermethylated
in placental tissues and could be detected as a fetal-specific DNA marker in maternal plasma. Detection of fetal trisomy 21
(T21) has been demonstrated by an epigenetic-genetic chromosome dosage approach where the amount of
hypermethylated HLCS in maternal plasma is normalized using a fetal genetic marker on the Y chromosome as a
chromosome dosage reference marker. We explore if this method can be applied on both male and female fetuses with the
use of a paternally-inherited fetal single nucleotide polymorphism (SNP) allele on a reference chromosome for chromosome
dosage normalization.
Methodology: We quantified hypermethylated HLCS molecules using methylation-sensitive restriction endonuclease
digestion followed by real-time or digital PCR analyses. For chromosome dosage analysis, we compared the amount of
digestion-resistant HLCS to that of a SNP allele (rs6636, a C/G SNP) that the fetus has inherited from the father but absent in
the pregnant mother.
Principal Findings: Using a fetal-specific SNP allele on a reference chromosome, we analyzed 20 euploid and nine T21
placental tissue samples. All samples with the fetal-specific C allele were correctly classified. One sample from each of the
euploid and T21 groups were misclassified when the fetal-specific G allele was used as the reference marker. We then
analyzed 33 euploid and 14 T21 maternal plasma samples. All but one sample from each of the euploid and T21 groups
were correctly classified using the fetal-specific C allele, while correct classification was achieved for all samples using the
fetal-specific G allele as the reference marker.
Conclusions: As a proof-of-concept study, we have demonstrated that the epigenetic-genetic chromosome dosage
approach can be applied to the prenatal diagnosis of trisomy 21 for both male and female fetuses.
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Introduction
The predominant reason for pregnant women to opt for
prenatal diagnosis is the possibility of fetal chromosomal
aneuploidies, in particular, trisomy 21 (T21, Down syndrome).
The use of invasive procedures to obtain fetal genetic materials for
a definitive diagnosis is associated with a finite risk of fetal loss
[1–3]. Noninvasive screening tests by ultrasonography and
maternal serum biochemical markers measure the epiphenomena
rather than the actual chromosome dosage of the fetus [4,5].
Despite a reasonably useful sensitivity and specificity profile, the
fact that prenatal screening tests are typically usable at a relatively
narrow gestational window and the need to combine multiple
markers have prompted workers to explore new approaches for
noninvasive prenatal diagnosis.
The discovery of cell-free fetal DNA in maternal plasma in 1997
has opened up new avenues for prenatal diagnosis [6,7]. Fetal
DNA exists as a minor fraction of background maternal DNA in
maternal plasma [8]. Nonetheless, detection of genetic markers
that the fetus has inherited from the father but are absent in the
pregnant mother have been implemented into clinical use. Such
qualitative assessments include the noninvasive determination of
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15244fetal rhesus D status [9,10] and exclusion of sex-linked disorders
[11]. However, detection of fetal chromosomal aneuploidies
requires precise quantitative measurements of the nucleic acid
molecules, and it has represented a challenge in the field.
Direct detection of fetal trisomy by allelic ratio analysis of single
nucleotide polymorphisms (SNPs) present in fetal-specific nucleic
acid markers in maternal plasma has been described with the
RNA-SNP approach [12–15] and epigenetic allelic ratio approach
[16]. The allelic ratio strategy targets a subset of nucleic acids
molecules that are representative of the fetal genome but present
in maternal plasma, e.g., placental mRNA transcripts [17–19] or
DNA molecules bearing a placenta-specific methylation signature
[20–24]. Since the fetus has to be heterozygous for the SNP to be
informative for allelic ratio analysis, the use of multiple markers is
required to increase the population coverage. However, it would
be time-consuming to develop such a list of markers because a
SNP has to be present within each fetal-specific marker in order to
use this approach.
Recently, noninvasive prenatal detection of fetal chromosomal
aneuploidies has been demonstrated with the highly precise
massively parallel genomic sequencing method [25–27]. By
counting an extremely large number of DNA molecules, e.g.,
millions of molecules, in a sample, the slight increment in genomic
representation from a trisomic chromosome derived from a
trisomic fetus could be detected [28]. Nonetheless, this is an
expensive approach with a relatively low throughput.
We have recently proposed a novel epigenetic-genetic chromo-
some dosage approach for fetal trisomy 21 detection using a fetal
epigenetic marker, the putative promoter of the holocarboxylase
synthetase (HLCS) gene (NM_000411) on chromosome 21, and a
fetal genetic marker, the zinc finger protein, Y-linked (ZFY) gene
(NM_003411) present on chromosome Y [29]. The rationale of
this approach is that the dosage of chromosome 21 in the genome
of the fetus is inferred by analyzing the amount of HLCS molecules
in maternal plasma and to normalize it to a genetic marker that is
fetal-specific in maternal plasma. To demonstrate that this method
can be used for both male and female fetuses, we have explored
the use of a paternally-inherited fetal SNP allele on a reference
chromosome to serve as the baseline for epigenetic-genetic
chromosome 21 dosage determination in place of the chromosome
Y marker.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethics approval was obtained from
the Joint Chinese University of Hong Kong – New Territories East
Cluster Clinical Research Ethical Committee and the King’s
College Hospital Ethics Committee. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
Study Participants
Women with euploid and T21 pregnancies who attended the
Department of Obstetrics and Gynaecology, Prince of Wales
Hospital and the King’s College Hospital, UK were recruited
between September 2004 and March 2010. Informed consent was
obtained from individuals who joined the study.
Chorionic villus samples (CVS) and amniotic fluid samples were
collected during conventional prenatal diagnosis sessions (gesta-
tional age: 12 to 18 weeks). Placental tissue samples were collected
from euploid third-trimester pregnancies after delivery (gestational
age: 37 to 40 weeks) and from T21 pregnancies after termination
of pregnancy (gestational age: 12 to 21 weeks). The chromosome
status of each T21 case was confirmed by full karyotyping.
Maternal peripheral blood samples (12 mL in EDTA tubes) were
collected from all subjects.
Processing of Blood and Tissue Samples
Peripheral blood samples were processed by a double
centrifugation protocol as previously described [30]. The blood
cell portion was recentrifuged at 2,500 g, and any residual plasma
was removed. All processed blood samples were stored at 280uC
until DNA extraction. DNA from the peripheral blood cells and
that from maternal plasma was extracted with the blood and body
fluid protocol of the QIAamp DNA Blood Mini Kit and the
QIAamp DSP DNA Blood Mini Kit, respectively (Qiagen).
Amniotic fluid samples were collected and stored at 4uC until
use. DNA from amniotic fluid was extracted with the blood and
body fluid protocol of the QIAamp DNA Blood Mini Kit
(Qiagen).
CVS and placental tissues were collected and stored at 280uC
until use. DNA from the CVS and placentas was extracted with
the QIAamp DNA Mini Kit (Qiagen) according to the
manufacturer’s tissue protocol.
Plasma and CVS samples collected at the King’s College
Hospital were processed and shipped on dry ice to Hong Kong for
molecular analysis.
Genotyping of the rs6636 SNP
Genotyping of the rs6636 SNP for the fetus (CVS, placental
tissue or amniotic fluid) and the mother (maternal blood cells) was
performed using a primer extension protocol as previously
described [16]. The sequences of the primers for genotyping are
listed in Table S1. Informative cases, defined as one in which the
fetus was heterozygous and the mother was homozygous for the
rs6636 SNP, were subjected to the epigenetic-genetic chromosome
dosage analysis.
Chromosome Dosage Analysis
The chromosome 21 and the reference markers in placental
tissue and maternal plasma DNA samples were quantified by
real-time quantitative polymerase chain reaction (qPCR) and
digital PCR [31], respectively. Chromosome dosage analysis was
performed by comparing the amount of hypermethylated HLCS
to that of a SNP allele (rs6636, a C/G SNP) that the fetus has
inherited from the father but absent in the pregnant mother. SNP
rs6636 is located within the transmembrane emp24 protein transport
domain containing 8 (TMED8) gene (AK095650) on chromosome 14
with an average heterozygosity of 0.452+/20.147 (dbSNP
build 131). rs6636 is one of the SNPs that we have previously
analyzed using mass spectrometry [32]. The rs6636 SNP assays
are denoted as rs6636-C/G SNP assays in this manuscript
(Figure 1).
Methylation-sensitive restriction endonuclease (MSRE)
digestion. A methylation-sensitive restriction endonuclease, BstUI
(New England Biolabs),was used to digest the hypomethylated DNA.
Extracted DNA was digested with the BstUI enzyme at 60uCf o r
16 hours. For CVS, placental tissues and maternal and normal
control blood cells, 40 U of BstUI enzyme was used to digest 100 ng
of DNA for the PCR assays. A mock-digested aliquot was included as
the digestion control. For mock-digestion, an equal amount of DNA
was subjected to the same digestion condition without the addition of
enzyme. For the plasma samples, 20 U to 60 U of the BstUI enzyme
was used to digest the DNA from 1.6–5.2 mL plasma.
Assay design and reaction conditions for real-time
quantitative PCR (qPCR) analysis. Real-time qPCR analysis
Autosomal Reference Marker for EGG
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primers and probes are listed in Table 1. Assays for the HLCS,
rs6636-C allele and rs6636-G allele were all performed in a
monoplex format. Within the PCR amplicon of the HLCS locus,
there were two BstUI enzyme recognition sites. In contrast, the
rs6636 SNP assays did not contain any BstUI enzyme recogni-
Figure 1. Schematic diagram of the HLCS and rs6636 SNP assays with the interpretation of the epigenetic-genetic (EGG) ratio. (A)
Left, the HLCS assay located in a CpG island on chr21:38352994-38353281 (reverse strand) of the February 2009 (hg19) assembly of the human
genome using the UCSC Genome Browser. Right, the rs6636 SNP assay located on chr14:77801610-77801705 (hg19). The relative positions of the
primers, probes, BstUI enzyme restriction sites and SNP of each assay are indicated. (B) EGG ratio can be measured by using the paternally-inherited,
fetal-specific SNP allele as reference. An elevation of the EGG ratio is observed in T21 in relation to the cutoff value (illustrated by the dotted line)
established from the euploid samples.
doi:10.1371/journal.pone.0015244.g001
Table 1. Oligonucleotide sequences for the HLCS, rs6636-C/G SNP and beta-actin PCR assays.
Assay Oligonucleotide Sequences (59 to 39)
PCR amplicon
length (bp)
HLCS Forward primer CCGTGTGGCCAGAGGTG 96
Reverse primer AAAGGGCCAGGTCGGGA
TaqMan probe (FAM) FAM-AGGATTTGGGGCTGCGC(MGB)
a
TaqMan probe (VIC) VIC-AGGATTTGGGGCTGCGC(MGB)
b
rs6636-C/G Forward primer TGGTAAGACTCTTAGAAATCACAGATGTT 96
Reverse primer GTATCCCAACTAATCATTTATTATGGTCA
TaqMan probe_ rs6636-C FAM-CCCCTATCATGAGAAAT(MGB)
TaqMan probe_ rs6636-G VIC-CCCCTATGATGAGAAAT(MGB)
Beta-actin Forward primer CCACCACCGCCGAGAC 96
Reverse primer TGGCCGGGCTTACCTGG
TaqMan probe FAM-AGCACAGAGCCTCGCC(MGB)
aFAM =6-carboxyfluorescein, MGB = minor-groove binding.
bVIC = Applied BiosystemsH proprietary dye.
doi:10.1371/journal.pone.0015244.t001
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Figure 1.
Each reaction was set up as a 25 mL mixture at a final
concentration of 16TaqManH Universal PCR Master Mix (Applied
Biosystems), 100 nM TaqManH probe (Applied Biosystems), and
300 nM of each of the forward and reverse primers (Integrated DNA
Technologies) with 25 ng DNA input. The reaction was initiated at
50uC for2 minand continued at 95uCfor10 minandfollowedby40
cycles of 95uC for 15 s and 60uC for 1 min. The experiments were
carried out on the 7300 Real-time PCR System (Applied Biosystems)
and the fluorescence data were collected and analyzed by the SDS
v1.3.0 software (Applied Biosystems). All reactions were run in
duplicates with the mean quantity taken. A calibration curve was
constructed by serially-diluted genomic DNA extracted from adult
male blood cells with concentration ranging from 10,000 genome
equivalents (GE) to 3 GE per reaction.
Assay design and reaction conditions for the digital PCR
analysis. The same oligonucleotide sequences for real-time PCR
analysis were used for the HLCS and rs6636-C/G SNP digital PCR
analyses (Table 1).Here, the HLCS assay was performed as a duplex
reaction with each of the rs6636-C/G SNP assays. The fluorescent
probeswerelabeled asHLCS(VIC) duplexwith rs6636-C(FAM)and
HLCS(FAM) duplex with rs6636-G(VIC).
The basis of the digital PCR analysis have been described
previously [13,33]. The total reaction volume was 5 mL per well in a
384-well plate at a final concentration of 16TaqManH Universal
PCR Master Mix (Applied Biosystems), 100 nM TaqManH probe
(Applied Biosystems), and 300 nM of each of the forward and
reverse primers (Integrated DNA Technologies). The reaction was
initiated at 50uC for 2 min and continued at 95uC for 10 min and
followed by 50 cycles of 95uC for 15 s and 60uC for 1 min. The
experiments were carried out on the 7900HT Sequence Detection
System (Applied Biosystems) in a 384-well format, and the
fluorescence data were collected by the ‘‘Absolute Quantification’’
application of SDS 2.3 software (Applied Biosystems).
Specificity of the rs6636-C/G SNP assay. Genomic DNA
extracted from placental tissues with known rs6636 genotypes
were subjected to the HLCS and rs6636 duplex assays. Samples
that were homozygous for one allele were tested with the rs6636-
C/G SNP assay for the other allele. A sample homozygous for the
C allele should not show any signals for the rs6636 assay detecting
the G allele, and vice versa.
Beta-actin assay as a digestion control
A previously-described beta-actin region which is unmethylated
in both the placenta and maternal blood cells was used to
determine the efficiency of BstUI digestion [34]. The beta-actin
assay was modified to contain two BstUI enzyme recognition sites
to match the number of BstUI enzyme recognition sites of the
current HLCS assay. The sequences of the primers and probes are
listed in Table 1. The same sequences were used for both the real-
time qPCR and digital PCR analyses.
Statistical analysis
Statistical analyses were performed using the SigmaStat 3.5
software (SPSS).
Results
Chromosome dosage analysis by conventional real-time
qPCR
The HLCS and rs6636-C/G SNP assays were applied to a total
of 20 euploid and nine T21 placental tissue samples with the
heterozygous C/G genotype. Six euploid and four T21 samples
were analyzed by using the HLCS to rs6636-C ratio, and the
remaining 14 euploid and five T21 samples were analyzed by the
HLCS to rs6636-G ratio. A calibration curve constructed by
serially-diluted genomic DNA extracted from adult male blood
cells with concentration ranging from 10,000 GE to 3 GE per
reaction was used to determine the absolute copy number of the
two loci in the tested samples.
All three assays were optimized to have similar efficiencies, as
indicated by the slopes and y-intercepts of the calibration curves.
The slopes of the calibration curves of the HLCS, rs6636-C and
rs6636-G assays were 23.71, 23.70 and 23.62, respectively,
whereas the y-intercepts showed threshold cycle values of 39.62,
39.79 and 42.04, respectively.
HLCS to rs6636-C ratio in placental DNA samples. The
HLCS to rs6636-C ratio was first determined in mock-digested
placental DNA samples. These included four male and two female
fetuses for the euploid, and three male and one female fetuses for
the T21 samples. A normal reference range, defined as the mean
HLCS to rs6636-C ratio 6 1.96SD, was calculated from the six
euploid samples as 1.78–2.66. All four T21 samples showed a
higher ratio than the normal reference range (Figure 2A).
The same samples were then subjected to BstUI restriction
enzyme digestion before real-time PCR analysis. While the
unmethylated HLCS molecules would be digested by BstUI
enzyme treatment, leaving only the digestion-resistant, hyper-
methylated HLCS molecules for PCR detection, the rs6636
molecules would remain intact as there was no BstUI enzyme
recognition site within the rs6636 PCR amplicon. A normal
reference range was calculated as 1.24–2.26. All samples were
correctly classified (Figure 2B).
In both the mock and BstUI digestion experiments, a placental
DNA sample, N2541, with the homozygous GG genotype for the
rs6636 SNP was included for testing the assay specificity. There
was no signal when the rs6636 assay for detecting the C allele was
applied (Table 2).
HLCS to rs6636-G ratio in placental DNA samples. The
HLCS to rs6636-G ratio was first determined in mock-digested
placental DNA samples. A normal reference range was calculated
from the 14 euploid samples as 1.36–3.03. One sample from each
of the euploid and T21 groups was misclassified (Figure 3A).
Among these samples, the euploid pregnancies consisted of eight
male and six female fetuses, while the T21 pregnancies had three
male and two female fetuses.
The same samples were then subjected to BstUI restriction
enzyme digestion before real-time PCR analysis. A normal
reference range was calculated as 0.90–1.99. One sample from
each of the euploid and T21 groups was misclassified (Figure 3B).
These are not the same samples as the misclassified ones in the
mock digestion experiment.
In both the mock and BstUI digestion experiments, a placental
DNA sample, N2582, with the homozygous CC genotype for the
rs6636 SNP was included for testing the assay specificity. There
was no signal when the rs6636 assay for detecting the G allele was
applied (Table 2).
Beta-actin as a digestion control. The BstUI enzyme
digestion efficiency was evaluated by applying the beta-actin assay
to the same mock- and BstUI-digested placental DNA samples as
those used for HLCS to rs6636 chromosome dosage analysis. The
same calibration standard was used to quantify the amount of beta-
actin sequences in the samples. The slope of the calibration curve
was 23.41, whereas the y-intercept showed threshold cycle value
of 37.97. Comparing the values of the corresponding pairs of
digested and mock-digested samples, over 96% of the DNA was
digested in all tested samples (Tables S2 and S3).
Autosomal Reference Marker for EGG
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e15244Chromosome dosage analysis by digital PCR
Specificity of the rs6636-C/G SNP assay. Placental DNA
samples of the heterozygous C/G, homozygous C/C and
homozygous G/G genotypes were tested with the HLCS and
rs6636 duplex assay to ascertain the specificity for detecting either
one of the SNP alleles. Two samples were used for each of the three
groups. A sample homozygous for the C allele should not show any
signals for the rs6636 assay detecting the G allele, and vice versa.
The number of wells that were positive for each of the target loci
was counted. The total number of molecules distributed into the
384-well plate followed the Poisson distribution, and was corrected
with the following equation: Target = -ln [E/N] 6 N, where
Target is the Poisson-corrected counts of the target molecules, E is
the number of negative (empty) wells, and N is the total number of
digital PCRs in the experiment.
By applying the HLCS and rs6636-C duplex assay, placental
DNA samples of the heterozygous C/G and homozygous C/C
genotypes showed positive wells for both loci, whereas samples of
the homozygous G/G genotypes were only positive for the HLCS
locus, and no detectable signal was observed for the rs6636-C
allele (Table 3).
By applying the HLCS and rs6636-G duplex assay, placental
DNA samples of the heterozygous C/G and homozygous G/G
genotypes showed positive wells for both loci, whereas samples of
homozygous C/C were only positive for the HLCS locus, and no
detectable signal was observed for the rs6636-G allele (Table 3).
Figure 2. Chromosome 21 dosage using rs6636-C allele as reference in euploid and T21 placental DNA samples. Ratio of (A) HLCS to
rs6636-C with mock digestion, and (B) HLCS to rs6636-C with BstUI digestion. The normal reference range is depicted by dotted lines. M, male fetus; F,
female fetus. PL, placenta.
doi:10.1371/journal.pone.0015244.g002
Table 2. Specificity of the rs6636-C/G SNP assays by real-time qPCR.
Assays: HLCS and rs6636-C
Treatment Sample rs6636 genotype Copies per reaction
HLCS rs6636-C
Mock digestion N2541 GG 4226 0
BstUI-digestion N2541 GG 4402 0
Assays: HLCS and rs6636-G
Treatment Sample rs6636 genotype Copies per reaction
HLCS rs6636-G
Mock digestion N2582 CC 2177 0
BstUI-digestion N2582 CC 1439 0
doi:10.1371/journal.pone.0015244.t002
Autosomal Reference Marker for EGG
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specific in detecting the individual SNP alleles. The specificity was
conferred by the allele-specific probes labeled with difference
fluorescent dyes.
HLCS to rs6636-C ratio in maternal plasma DNA
samples. Maternal plasma DNA analysis was performed by
comparing the ratio of digestion-resistant HLCS to fetal-specific
rs6636 SNP allele in informative samples. An informative sample
was defined as one in which the fetus was heterozygous and the
mother was homozygous, being the rs6636-C/G SNP in the
current example. The allele that the fetus had inherited from the
father, and absent in the maternal genome, was used as the
reference baseline for chromosome 21 dosage determination.
The HLCS and rs6636-C duplex assay was applied to a total of
18 euploid and six T21 pregnancies. In these samples, the fetal and
maternal genotypes for the rs6636 SNP were C/G and G/G,
respectively. The fetal-specific SNP allele was the C allele.
Maternal plasma DNA samples were analyzed by digital PCR
after BstUI enzyme digestion. The total number of positive wells
was used to calculate the ratio of HLCS to rs6636-C allele in each
sample.
A normal reference range of 2.09–3.85 was calculated from the
euploid maternal plasma samples. Nine, five and four samples
were collected from the third, second- and first-trimester
pregnancies, respectively. Among these 18 euploid samples, eight
were from pregnancies carrying a male fetus, and ten from those
carrying a female fetus with no gestational bias. The HLCS to
rs6636-C allele ratios of all but one euploid sample fell within the
reference range. A total of six T21 samples (one male and five
female fetuses) were analyzed with the EGG approach, all but one
sample had a ratio greater than the upper limit (Figure 4A).
HLCS to rs6636-G ratio in maternal plasma DNA
samples. In the other group of informative samples, the fetal
Figure 3. Chromosome 21 dosage using rs6636-G allele as reference in euploid and T21 placental DNA samples. Ratio of (A) HLCS to
rs6636-G with mock digestion, and (B) HLCS to rs6636-G with BstUI digestion. The normal reference range is depicted by dotted lines. M, male fetus; F,
female fetus. PL, placenta.
doi:10.1371/journal.pone.0015244.g003
Table 3. Specificity of the rs6636-C/G SNP assays by digital
PCR.
Assays: duplex HLCS and rs6636-C
Sample
rs6636
genotype Copies/run*
No. of PCR
wells analyzed
HLCS rs6636-C
Placenta 1 CG 41 29 192
Placenta 2 CG 95 46 192
Placenta 3 CC 76 87 192
Placenta 4 CC 28 20 192
Placenta 5 GG 39 0 192
Placenta 6 GG 13 0 192
Assays: duplex HLCS and rs6636-G
Sample
rs6636
genotype Copies/run
No. of PCR
wells analyzed
HLCS rs6636-G
Placenta 1 CG 82 37 192
Placenta 2 CG 76 40 192
Placenta 3 CC 192 0 384
Placenta 4 CC 83 0 384
Placenta 5 GG 51 53 192
Placenta 6 GG 45 47 192
*The output for digital PCR is an ‘‘all-or-nothing’’ readout of individual
amplification. The numbers of positive wells were counted for each target. With
reference to the number of PCR wells analyzed, the copy numbers were corrected
for the Poisson distribution using the formula shown in the Results section.
doi:10.1371/journal.pone.0015244.t003
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PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15244and maternal genotypes for the rs6636 SNP were C/G and C/C,
respectively. The fetal-specific SNP allele was the G allele. The
HLCS and rs6636-G duplex digital PCR assay was applied to
BstUI-digested maternal plasma DNA samples from 15 euploid
pregnancies and eight T21 pregnancy. The total number of
positive wells was used to calculate the ratio of HLCS to rs6636-G
allele in each sample.
A normal reference range of 2.06–3.74 was calculated from
euploid maternal plasma samples. Among the 15 euploid samples,
five, six and four cases were collected from the third-, second- and
first-trimester pregnancies, respectively. There were seven preg-
nancies with a male fetus, and eight with a female fetus. The HLCS
to rs6636-G allele ratios of all euploid samples fell within the
reference range. A total of eight T21 samples (six male and two
female fetuses) were analyzed with correct classification for all
samples (Figure 4B).
Beta-actin as a digestion control. The BstUI enzyme
digestion efficiency was evaluated by applying the beta-actin
digital PCR assay to the same BstUI-digested maternal plasma
DNA samples as those used for the HLCS to rs6636 chromosome
dosage analysis. An aliquot of the digested DNA samples (1/50 of
the total digestion mixture) was confirmed to show no positive well
for the beta-actin assay before being subjected to chromosome
dosage analysis. If the results showed any positive digital PCR well,
we would re-digest the plasma DNA to ensure that no control
signal of beta-actin was detected.
Discussion
We have recently demonstrated in principle that the EGG
approach was a feasible method for fetal chromosomedosage analysis
in maternal plasma DNA samples [29]. The hypermethylated HLCS
locus was used as the epigenetic component, which represented a
class of fetal-specific molecules, and the ZFY locus was a genetic
marker which was specific to a male fetus. By comparing the ratio
between the fetal-specific epigenetic marker on chromosome 21 and
the fetal-specific genetic marker on a reference chromosome, the
chromosome 21 dosage could be deduced.
In this paper, we further demonstrated that the epigenetic-
genetic chromosome dosage approach can be applied to the
prenatal diagnosis of trisomy 21 using a fetal-specific SNP allele as
a genetic reference baseline in place of a chromosome Y marker
derived from a male fetus. Here, SNP rs6636 located on
chromosome 14 was used as an example. By comparing the ratio
between the hypermethylated HLCS and the fetal-specific rs6636
SNP allele, the chromosome 21 dosage could be deduced in the
majority of samples analyzed.
During the past few years, several methods have been proposed
for the direct detection of fetal chromosomal aneuploidies by
maternal plasma analysis. The earliest reports relied on measuring
the allelic ratios of SNPs present in fetal-specific nucleic acid
markers [12,16]. Analysis of the allelic ratio approach requires the
discrimination of an allelic ratio of 1:1 in a euploid and 2:1 in a
trisomy fetus within a single locus. However, this approach is only
applicable to fetuses who are heterozygous for the analyzed SNP
located within the fetal-specific marker, thus limiting its population
coverage. The EGG approach described in the present study also
involves the measurement of an increase in the chromosome dosage
in trisomy versus euploid pregnancies. However, it bypasses the
requirement of the allelic ratio approach for both the fetal-specific
marker and the SNP to be present in the same locus [29]. Since the
number of fetal DNA molecules in maternal plasma is limited,
identification of multiple markers to perform multiplex PCR
analysis is suggested to increase the number of molecules that can
Figure 4. Chromosome 21 dosage determination in BstUI-digested, euploid and trisomy 21 maternal plasma DNA samples. Ratio of
(A) hypermethylated HLCS to rs6636-C allele, and (B) hypermethylated HLCS to rs6636-G allele. The normal reference range is depicted by dotted
lines. M, male fetus; F, female fetus.
doi:10.1371/journal.pone.0015244.g004
Autosomal Reference Marker for EGG
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15244be counted and hence improving the precision for the EGG ratio
estimation. The quantitative precision of single molecule counting
also opens up another class of methods for fetal trisomy detection
that is independent of fetal-specific markers. These methods allow
the detection of small quantitative perturbations in the genomic
representation of plasma DNA. Examples of such approaches are
those based on relative chromosome dosage analysis by digital PCR
[13], and more recently, massively parallel genomic sequencing
[25,26]. The latter approach, in particular, appears to be very
sensitive and specific, is limited by a high cost and relatively low
throughput in the present laboratory settings.
Concerning the technical issues on the current development of
EGG analysis, results from placental DNA analysis showed that
one sample from each of the euploid and T21 groups were
misclassified. Imprecision could be introduced by the use of
monoplex conventional real-time PCR to measure the copy
number for the HLCS and SNP loci to determine the epigenetic-
genetic ratio. In light of this concern, we optimized the maternal
plasma DNA analysis using duplex digital PCR assays. Despite a
low concentration of fetal DNA in maternal plasma (typically,
samples from early gestation had fewer than 50 copies of the
paternally-inherited fetal SNP allele for analysis), only two samples
were misclassified in a total of 47 maternal plasma DNA samples.
Another technical issue was related to the choice of the digital
PCR platform. The microfluidics digital PCR platform that we
used previously contained a dead volume of about 50% [33]. The
dead volume refers to the amount of reaction mixture that could
not reach the partitioned PCR chambers due to the design of the
system. As a result, half of the input DNA molecules would not be
analyzed. Since the concentration of fetal DNA in maternal
plasma is low, we switched to the more labor-intensive 384-well
plate format for digital PCR analysis. We directly pipetted the
template-containing reaction mixture into the PCR wells and
hence the total volume of the reaction mixture could be analyzed.
It is believed that an improved microfluidics digital PCR platform
without dead volume would enhance the efficiency of the
epigenetic-genetic chromosome dosage analysis.
In conclusion, we have shown that by using an informative SNP
allele as the genetic reference baseline, the EGG chromosome
dosage approach could be applied to the prenatal diagnosis of
trisomy 21 for both male and female fetuses. Furthermore,
development of a panel of genetic reference markers would allow
broad population coverage of this approach. As previously
described [32], one could first test a maternal buffy coat sample,
which comprises mostly of maternal DNA, to ascertain the
maternal genotypes for the panel of SNPs. For SNPs for which the
mother is shown to be homozygous, one can then aim to detect the
allele that is not represented in the maternal genotype in maternal
plasma. If the plasma sample is positive for the non-maternal
allele, it suggests that the fetus has inherited that allele from the
father. The quantification of that paternally inherited fetal-specific
allele in maternal plasma could then be used as the reference for
gene dosage assessment using the epigenetic-genetic approach.
Finally, the use of epigenetic markers for the other chromosomes
involved in other aneuploidies important for prenatal testing, e.g.
chromosomes 18 and 13, would further expand the clinical utility
of the EGG approach.
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